Price$4.96-0.14 (-2.84%)
01:30 PM07:45 PM
News · 26 weeks40+80%
2025-12-072026-05-31
Mix1890d
- SEC Filings6(33%)
- Other4(22%)
- Leadership3(17%)
- Insider3(17%)
- Earnings2(11%)
Latest news
25 items- SECSEC Form DEFA14A filed by OptimizeRx CorporationDEFA14A - OptimizeRx Corp (0001448431) (Filer)
- PROptimizeRx to Participate in Upcoming Investor ConferencesWALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference, Boston, June 2 – 3, 202646th Annual William Blair Growth Stock Conference, Chicago, June 2 – 4, 2026 Stifel 2026 Boston Cross Sector 1x1 ConferenceDate: Tuesday, June 2, 2026 Format: 1x1 Meetings Location: InterContinental Boston William Blair & Company's 46th Annual Growth Stock ConferenceDate: Wednesday, June
- PRDeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR NetworkWALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced that DeepIntent, the leading healthcare demand-side platform (DSP), will be the first DSP to integrate OptimizeRx's proprietary electronic health record (EHR) network into its healthcare advertising platform. By combining OptimizeRx's authenticated EHR network with DeepIntent's healthcare-first DSP capabilities, this collaboration gives life sciences marketers an easier way to activate advertising within HCP wor
- INSIDERChief Commercial Officer Greco Theresa covered exercise/tax liability with 1,793 shares, decreasing direct ownership by 2% to 71,075 units (SEC Form 4) (withholding obligation)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Executive Officer Silvestro Stephen L covered exercise/tax liability with 5,219 shares, decreasing direct ownership by 3% to 185,288 units (SEC Form 4) to satisfy withholding tax4 - OptimizeRx Corp (0001448431) (Issuer)
- SECSEC Form 10-Q filed by OptimizeRx Corporation10-Q - OptimizeRx Corp (0001448431) (Filer)
- SECOptimizeRx Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - OptimizeRx Corp (0001448431) (Filer)
- PROptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance– Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million– Paid off an incremental $2.7 million in principal from term loan during Q1– Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings– Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "
- PROptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at ScaleWALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced the launch of a new programmatic connection point between OptimizeRx's proprietary EHR network and DSPs, enabling media buyers to activate scalable, point of care campaigns within their existing programmatic workflows. This launch also opens up new access for OptimizeRx to the programmatic market, estimated at 90% of the total U.S. digital display ad spend across all industries. Bridging Point of C
- SECSEC Form DEF 14A filed by OptimizeRx CorporationDEF 14A - OptimizeRx Corp (0001448431) (Filer)
- PROptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) ReportWALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2026. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibilities as a corporate citizen. ESG Report Highlights The appointment of Mary Varghese Presti to our Board of Directors as an independent director furthers our ongoing process to refresh
- PROptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ETWALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2026. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Tuesday, May 12, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Toll Free: 1-
- INSIDERSEC Form 3 filed by new insider Presti Mariyamma Varghese3 - OptimizeRx Corp (0001448431) (Issuer)
- PRMyomo Appoints William J Febbo to its Board of DirectorsMyomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William "Will" Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant ca
- PROptimizeRx Appoints Mary Varghese Presti to Board of DirectorsWALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Mary Varghese Presti to its Board of Directors. The appointment of Varghese Presti as an independent director is in furtherance of the Company's ongoing process to refresh and expand its Board of Directors. Varghese Presti brings more than 25 years of experience at the intersection of healthcare, life sciences, and technology, with a track record of building and scaling platforms that translate innovation into real-world
- SECOptimizeRx Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - OptimizeRx Corp (0001448431) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by OptimizeRx CorporationSCHEDULE 13G/A - OptimizeRx Corp (0001448431) (Subject)
- SECSEC Form 10-K filed by OptimizeRx Corporation10-K - OptimizeRx Corp (0001448431) (Filer)
- PRUPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today
- SECOptimizeRx Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - OptimizeRx Corp (0001448431) (Filer)
- PROptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today
- INSIDERChief Legal & Admin Officer Odence-Ford Marion converted options into 4,000 shares and covered exercise/tax liability with 1,386 shares, increasing direct ownership by 3% to 91,936 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- PROptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ETWALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Thursday, March 5, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific T
- PROptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare MarketingWALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data and technology company. This integration maps OptimizeRx Micro-Neighborhood® audiences to Experian's identity graph, enabling seamless onboarding and curated audience activation, delivering a transparent, reliable methodology for life sciences brands and healthcare marketing agencies to reach and measure consumer audiences at scale. Addressing Fragmentation that
- INSIDERAmendment: Chief Executive Officer Silvestro Stephen L covered exercise/tax liability with 3,361 shares, decreasing direct ownership by 2% to 190,507 units (SEC Form 4)4/A - OptimizeRx Corp (0001448431) (Issuer)
OPRX FAQ
6 questionsWhat does OptimizeRx Corporation do?
OptimizeRx Corporation operates as a digital health company that provides communications solutions for life science companies, physicians, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, therapeutic support messages, and unbranded messages. The company also offers brand support...Where does OPRX stock trade?
OptimizeRx Corporation (OPRX) is listed on NASDAQ.What sector and industry is OPRX in?
OptimizeRx Corporation operates in the Real Estate sector.What are analysts saying about OPRX?
OptimizeRx Corporation has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform with a $600.00 price target on 2025-01-08.What companies are similar to OPRX?
Notable peers in the same industry include V (Visa Inc.), MA (Mastercard Incorporated), BABA (Alibaba Group Holding Limited), UBER (Uber Technologies Inc.), ACN (Accenture plc). Compare OPRX side-by-side with any of them on Quantisnow.How can I track OPRX on Quantisnow?
Quantisnow aggregates OptimizeRx Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OPRX to receive live email and push alerts on every new disclosure.